Pfizer (PFE) Reports Positive CHMP Opinion for Vizimpro (dacomitinib) Positive CHMP Opinion for Vizimpro (dacomitinib) for 1st-Line Treatment of Adult Patients

February 1, 2019 9:21 AM
Pfizer (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles